Korro Bio
KRRO
41 hedge funds and large institutions have $12.6M invested in Korro Bio in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 7 closing their positions.
653% more capital invested
Capital invested by funds: $1.67M → $12.6M (+$10.9M)
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0.31% more ownership
Funds ownership: 0.27% → 0.58% (+0.31%)
0% more funds holding
Funds holding: 41 → 41 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
Top Buyers
Top Sellers
| 1 |
GS
GTS Securities
New York
|
-$77.3K |
| 2 |
Millennium Management
New York
|
-$28.8K |
| 3 |
BlackRock
New York
|
-$27.3K |
| 4 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
-$14.8K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$11.6K |
KRRO Hedge Fund Activity: Q3 2023 in Review
41 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Korro Bio (KRRO) for Q3 2023, worth a combined $12.6M — up 653% from $1.67M a quarter earlier.
Fund positioning in KRRO was balanced in Q3 2023: 7 funds opened new positions, 7 closed out, 7 added to existing stakes and 4 trimmed.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $1.8M. The largest seller was GTS Securities, exiting entirely with an estimated $77.3K sold.
- 41 institutional investors held Korro Bio (KRRO) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $12.6M of Korro Bio stock for Q3 2023, up 653% quarter-over-quarter.
- 7 funds opened new Korro Bio positions in Q3 2023 and 7 closed out, a net change of 0 holders.
- The largest Korro Bio buyer in Q3 2023 was Eventide Asset Management, an estimated $1.8M added.
- The largest Korro Bio seller in Q3 2023 was GTS Securities, an estimated $77.3K sold.
Based on aggregated 13F filings for Q3 2023.